Focal Segmental Glomerulosclerosis Market: Efforts by NGOs to Generate Awareness about FSGS to Bolster Market
The focal segmental glomerulosclerosis (FSGS) market is highly competitive due to presence of numerous large players and presence of local players. Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., and Retrophin, Inc. The global focal segmental glomerulosclerosis (FSGS) market will likely see continued changes in its contours with the successful launch of pipeline products in the next couple of years.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31505
As per a report by Transparency Market Research, the global focal segmental glomerulosclerosis (FSGS) market will likely rise at a solid 8.0% CAGR over the course of the forecast period from 2017 to 2025. Expanding at this pace, the market which was worth US$7.82 bn in 2016, is projected to attain a value of US$15.83 bn by 2025-end. Based upon the type of disease, the market can be bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis.
Between the two, the primary focal segmental glomerulosclerosis held a substantial 79.8% share in the market in 2016. Growing awareness about the disease and its management is at the forefront of driving growth in the segment. North America, of them, leads with a dominant share on the back of a properly structured healthcare industry and availability of reimbursement policies with wider coverage.
Request for Analysis of COVID19 Impact on Focal Segmental Glomerulosclerosis (FSGS) Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31505
Rising Instances of the Rare Disease Boosts Demand in Market
Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death. FSGS advances much more swiftly than diabetic nephropathy. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease. Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.
“Focal segmental glomerulosclerosis affects approximately 210,200 patients worldwide with 14,000 to 16,000 new cases every year. This has been a major growth driver in the market.
Request for Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=31505
Efforts by NGOs to Generate Awareness about FSGS to Bolster Market
Apart from the rising cases of the medical condition, other factors that can benefit the market are efforts by non-government organizations to increase awareness and increasing allocation towards research on rare diseases. NephCure Kidney International, The Kidney & Urology Foundation of America (KUFA), EURORDIS, and The National Organization for Rare Disorders (NORD) are some of the non-governmental organizations that are helping out patients with focal segmental glomerulosclerosis and generating awareness about the disease. Besides, research in the renal treatment field have resulted in several new drugs being developed and approved every year.
Buy Focal Segmental Glomerulosclerosis (FSGS) Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=31505<ype=S
Rising kidney transplants and dialysis procedures are other factors promoting the said market. As per the analyst, the market holds out a lot of opportunity due to a limited number of pipeline products at present.
Browse More Trending Reports by Transparency Market Research:
Microbial Sealants Market: https://www.transparencymarketresearch.com/microbial-sealants-market.html
PDE Inhibitors Market: https://www.transparencymarketresearch.com/pde-inhibitors-market.html
Squamous Cell Carcinoma Treatment Market: https://www.transparencymarketresearch.com/squamous-cell-carcinoma-treatment-market.html
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Mr. Rohit Bhisey
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453